We use cookies for a better user experience. Read our Privacy Policy
I Agree
Hypopigmentation Disorder Treatment Market
Increase in the number of vitiligo patients, expanding awareness pertaining to hypopigmentation disorders, and rise in new product launches by key players are generating substantial business opportunities in the global hypopigmentation disorder treatment market.
In the health condition hypopigmentation, an individual has skin patches of lighter color than the overall skin color. The health conditions such as albinism and vitiligo can be experienced by an individual due to several reasons such as injury, disease, burns, or other traumas.
For treating albinism and vitiligo, several treatment solutions such as laser therapy, topical drugs, microdermabrasion, chemical peels, and phototherapy are used. These treatments are available in aesthetic clinics & dermatology centers and hospitals.
Enterprises from the global hypopigmentation disorder treatment market are expected to observe surge in the product demand from aesthetic clinics & dermatology centers, due to rise in the number of qualified physicians carrying out different cosmetic procedures used in the pigmentation disorders treatments.
Companies in the global hypopigmentation disorder treatment market are increasing investments in the R&D projects in order to advance the quality of products they offer. Moreover, several players are focused on collaboration and acquisition strategies and maintaining their leading positions in the global market for hypopigmentation disorder treatment.
Players in hypopigmentation disorder treatment market are creating newer policies and strategies that focus on recovering from the losses companies encountered due to the COVID-19 pandemic. Key players operating in the global hypopigmentation disorder treatment market are Allergan, SkinCeuticals, Episciences, Inc., Obagi Cosmeceuticals LLC (Obagi Medical), Pierre Fabre, Alvogen, and RXi Pharmaceuticals Corporation.
The hypopigmentation disorder treatment market is expected to gain lucrative opportunities in the North America region. This market growth can be ascribed to many factors such as presence of strong healthcare infrastructure, considerable number of patient pool, and new product approvals in the region.
The global hypopigmentation disorder treatment market is driven by the rise in prevalence of vitiligo. Growth of the market is attributed to increase in awareness about hypopigmentation disorders and rich product pipeline.
Hypopigmentation is characterized by patches of skin that are lighter than the overall skin tone. The absence of normal amount of melanin (chemical that gives skin its color) caused by disease, injury, burns, or other trauma could lead to hypopigmentation. Hypopigmentation disorders include vitiligo and albinism. Treatments of this disease include topical drugs, laser therapy, chemical peels, microdermabrasion, and others (phototherapy, etc.). Rise in prevalence of acute hypopigmentation disorders such as vitiligo and albinism is anticipated to increase demand for therapeutics, which in turn is expected to drive the global hypopigmentation disorder treatment market. According to the Global Vitiligo Foundation, currently, 70 million people across the world have vitiligo. Moreover, increase in health care expenditure and rise in the number of clinical trials are expected to propel the global hypopigmentation disorder treatment market.
The global hypopigmentation disorder treatment market has been segmented based on treatment, end-user, and region. In terms of treatment, the global market has been classified into topical drugs, laser therapy, chemical peels, microdermabrasion, and others (phototherapy, etc.). The topical drugs segment accounted for major share of the global market in terms of revenue in 2017. The segment is projected to expand at a high CAGR during the forecast period due to increase in the number of patients with hypopigmentation disorders visiting dermatologists and topical drugs being prescribed to these patients. Based on disease indication, the global hypopigmentation disorder treatment market has been categorized into vitiligo, albinism, and others. The vitiligo segment dominated the global market in 2017 due to rise in the number of patients undergoing treatment for vitiligo.
In terms of end-user, the global hypopigmentation disorder treatment market has been divided into hospitals, aesthetic clinics & dermatology centers, and others. The aesthetic clinics & dermatology centers segment dominated the global market in 2017. The trend is likely to continue during the forecast period. Factors driving the segment are increase in the number of trained physicians who can perform cosmetic procedures to treat pigmentation disorders and rise in the number of patients with skin pigmentation.
In terms of region, the global hypopigmentation disorder treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017 and is projected to gain market share from 2018 to 2026. The market in North America is driven by increase in incidence of hypopigmentation disorders, new product approvals, strong product pipeline, and rise in health care expenditure. The hypopigmentation disorder treatment market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period. China dominated the market in the region in 2017 due to high population of patients with vitiligo.
Major players operating in the global hypopigmentation disorder treatment market include Allergan, SkinCeuticals, Pierre Fabre, Episciences, Inc., RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC (Obagi Medical), and Alvogen. These companies have adopted the strategy of acquisition and collaboration to strengthen their positions in the global market.
Rising Number of Clinical Trials Paves Way for Innovation in Hypopigmentation Disorder Treatment Market
Drive for improvements and technological advancements in healthcare infrastructure, along with rising number of clinical trials to derive efficient solutions for treatment of hypopigmentation disorders is fueling a wave of innovations in global hypopigmentation disorder treatment market. The growth of global pharmaceutical industry indirectly bolsters the growth in the market as well. Other factors influencing the increase in demand in hypopigmentation disorder treatment market include rising prevalence of Vitiligo and availability of cost effective treatment options. However, substantial cost of treatment and risks and complications associated with aesthetic treatments and products can hamper the growth of global hypopigmentation disorder treatment market in coming years. Risk of side effects of cosmetics and hypopigmentation disorders treatments is also a concerning factor for the patients.
Rising demand for effective and affordable hypopigmentation disorder treatment solutions is expected to provide players in global hypopigmentation disorder treatment market with various opportunities for business development. Players in the market are increasingly focused on developing new topical drugs to meet the rising demand. For example, a brand of A. Menarini Singapore Pvt. Ltd., Dermatix, launched a new acne scare care product, that consists of Vitamin B3 to reduce effects of hypopigmentation disorders. Lower cost and higher effectiveness of topical drugs makes them a lucrative treatment option for patients suffering from hypopigmentation disorders. Increasing popularity of chemical peels among partitioning dermatologists and their patients is also anticipated to increase sales in this particular segment in global hypopigmentation disorder treatment market. Treatments such as microdermabrasion and laser therapy have higher costs and therefore can be afforded by very little consumers. However, increasing adoption of these treatment techniques by professionals and rising number of dermatology centers and aesthetic clinics investing in newer devices are anticipated to draw demand in this segment in global hypopigmentation disorder treatment market. Increasing government initiatives designed to disseminate awareness and information regarding skin pigment disorders including vitiligo and albinism are also expected to drive the global hypopigmentation disorder treatment market in coming years.
The global hypopigmentation disorder treatment market has been segmented as below:
|
Treatment |
|
|
Disease Indication
|
|
|
End-user
|
|
|
Region |
|
The global hypopigmentation disorder treatment market was worth US$ 1,277.7 Mn and is projected to reach a value of US$ 2,138.6 Mn by the end of 2026
Hypopigmentation disorder treatment market is anticipated to grow at a CAGR of 5.9% during the forecast period
North America accounted for a major share of the global hypopigmentation disorder treatment market
Rise in prevalence of acute hypopigmentation disorders such as vitiligo and albinism is anticipated to increase demand for therapeutics, which in turn is expected to drive the global hypopigmentation disorder treatment market
Key players in the global hypopigmentation disorder treatment market include Allergan, SkinCeuticals, Pierre Fabre, Episciences, Inc., RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC (Obagi Medical), and Alvogen
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Market Overview
4.2. Global Hypopigmentation Disorders Treatment Market Analysis
4.3. Global Hypopigmentation Disorders Treatment Market Overview
4.4. Porter’s Five Forces Analysis
4.5. Pipeline Analysis
4.6. Key Partnership & Acquisitions
4.7. Disease Prevalence and Incidence: Global Overview
4.8. Regulatory Scenario
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Key Trends
6. Global Hypopigmentation Disorders Treatment Market Analysis, by Treatment
6.1. Introduction
6.2. Global Hypopigmentation Disorders Treatment Market Value Share Analysis, by Treatment
6.3. Global Hypopigmentation Disorders Treatment Market Forecast, by Treatment
6.4. Global Hypopigmentation Disorders Treatment Market Analysis, by Treatment
6.4.1. Topical Drugs
6.4.2. Laser Therapy
6.4.3. Chemical Peels
6.4.4. Microdermabrasion
6.4.5. Others (phototherapy, etc.)
6.5. Global Hypopigmentation Disorders Treatment Market Attractiveness Analysis, by Treatment
7. Global Hypopigmentation Disorders Treatment Market Analysis, by Disease Indication
7.1. Introduction
7.2. Global Hypopigmentation Disorders Treatment Market Value Share Analysis, by Disease Indication
7.3. Global Hypopigmentation Disorders Treatment Market Forecast, by Disease Indication
7.4. Global Hypopigmentation Disorders Treatment Market Analysis, by Disease Indication
7.4.1. Vitiligo
7.4.2. Albinism
7.4.3. Others
7.5. Global Hypopigmentation Disorders Treatment Market Attractiveness Analysis
8. Global Hypopigmentation Disorders Treatment Market Analysis, by End-user
8.1. Introduction
8.2. Global Hypopigmentation Disorders Treatment Market Value Share Analysis, by End-user
8.3. Global Hypopigmentation Disorders Treatment Market Forecast, by End-user
8.4. Global Hypopigmentation Disorders Treatment Market Analysis, by End-user
8.4.1. Hospitals
8.4.2. Aesthetic Clinics & Dermatology Centers
8.4.3. Others
8.5. Global Hypopigmentation Disorders Treatment Market Attractiveness Analysis, by End-user
9. Global Hypopigmentation Disorders Treatment Market Analysis, by Region
9.1. Global Market Scenario
9.2. Global Hypopigmentation Disorders Treatment Market Value Share Analysis, by Region
9.3. Global Hypopigmentation Disorders Treatment Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Global Hypopigmentation Disorders Treatment Market Attractiveness Analysis, by Region
10. North America Hypopigmentation Disorders Treatment Market Analysis
10.1. North America Hypopigmentation Disorders Treatment Market Analysis
10.2. North America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Country
10.3. North America Hypopigmentation Disorders Treatment Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Treatment
10.5. North America Hypopigmentation Disorders Treatment Market Forecast, by Treatment
10.5.1. Topical Drugs
10.5.2. Laser Therapy
10.5.3. Chemical Peels
10.5.4. Microdermabrasion
10.5.5. Others (phototherapy, etc.)
10.6. North America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
10.7. North America Hypopigmentation Disorders Treatment Market Forecast, by Disease Indication
10.7.1. Vitiligo
10.7.2. Albinism
10.7.3. Others
10.8. North America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by End-user
10.8.1. Hospitals
10.8.2. Aesthetic Clinics & Dermatology Centers
10.8.3. Others
11. Europe Hypopigmentation Disorders Treatment Market Analysis
11.1. Europe Hypopigmentation Disorders Treatment Market Analysis
11.2. Europe Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Europe Hypopigmentation Disorders Treatment Market Forecast, by Country/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Treatment
11.5. Europe Hypopigmentation Disorders Treatment Market Forecast, by Treatment
11.5.1. Topical Drugs
11.5.2. Laser Therapy
11.5.3. Chemical Peels
11.5.4. Microdermabrasion
11.5.5. Others (phototherapy, etc.)
11.6. Europe Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
11.7. Europe Hypopigmentation Disorders Treatment Market Forecast, by Disease Indication
11.7.1. Vitiligo
11.7.2. Albinism
11.7.3. Others
11.8. Europe Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by End-user
11.8.1. Hospitals
11.8.2. Aesthetic Clinics & Dermatology Centers
11.8.3. Others
12. Asia Pacific Hypopigmentation Disorders Treatment Market Analysis
12.1. Asia Pacific Hypopigmentation Disorders Treatment Market Analysis
12.2. Asia Pacific Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Asia Pacific Hypopigmentation Disorders Treatment Market Forecast, by Country/Sub-region
12.3.1. China
12.3.2. Japan
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Treatment
12.5. Asia Pacific Hypopigmentation Disorders Treatment Market Forecast, by Treatment
12.5.1. Topical Drugs
12.5.2. Laser Therapy
12.5.3. Chemical Peels
12.5.4. Microdermabrasion
12.5.5. Others (phototherapy, etc.)
12.6. Asia Pacific Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
12.7. Asia Pacific Hypopigmentation Disorders Treatment Market Forecast, by Disease Indication
12.7.1. Vitiligo
12.7.2. Albinism
12.7.3. Others
12.8. Asia Pacific Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by End-user
12.8.1. Hospitals
12.8.2. Aesthetic Clinics & Dermatology Centers
12.8.3. Others
13. Latin America Hypopigmentation Disorders Treatment Market Analysis
13.1. Latin America Hypopigmentation Disorders Treatment Market Analysis
13.2. Latin America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Latin America Hypopigmentation Disorders Treatment Market Forecast, by Country/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Treatment
13.5. Latin America Hypopigmentation Disorders Treatment Market Forecast, by Treatment
13.5.1. Topical Drugs
13.5.2. Laser Therapy
13.5.3. Chemical Peels
13.5.4. Microdermabrasion
13.5.5. Others (phototherapy, etc.)
13.6. Latin America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
13.7. Latin America Hypopigmentation Disorders Treatment Market Forecast, by Disease Indication
13.7.1. Vitiligo
13.7.2. Albinism
13.7.3. Others
13.8. Latin America Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by End-user
13.8.1. Hospitals
13.8.2. Aesthetic Clinics & Dermatology Centers
13.8.3. Others
14. Middle East & Africa Hypopigmentation Disorders Treatment Market Analysis
14.1. Middle East & Africa Hypopigmentation Disorders Treatment Market Analysis
14.2. Middle East & Africa Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3. Middle East & Africa Hypopigmentation Disorders Treatment Market Forecast, by Country/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of MEA
14.4. Middle East & Africa Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Treatment
14.5. Middle East & Africa Hypopigmentation Disorders Treatment Market Forecast, by Treatment
14.5.1. Topical Drugs
14.5.2. Laser Therapy
14.5.3. Chemical Peels
14.5.4. Microdermabrasion
14.5.5. Others (phototherapy, etc.)
14.6. Middle East & Africa Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
14.7. Middle East & Africa Hypopigmentation Disorders Treatment Market Forecast, by Disease Indication
14.7.1. Vitiligo
14.7.2. Albinism
14.7.3. Others
14.8. Middle East & Africa Hypopigmentation Disorders Treatment Market Value Share and Attractiveness Analysis, by End-user
14.8.1. Hospitals
14.8.2. Aesthetic Clinics & Dermatology Centers
14.8.3. Others
15. Competition Landscape
15.1. Hypopigmentation Disorders Treatment Market Share Analysis, by Company
15.2. Competition Matrix
15.3. Company Profile
15.3.1. Allergan
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. SkinCeuticals
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Pierre Fabre
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Episciences, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Rxi Pharmaceutical Corporation
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Obagi Cosmeceuticals LLC (Obagi Medical)
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Alvogen
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
List of Tables
Table 01: Global Hypopigmentation Disorders Treatment Market: Pipeline Analysis
Table 02: Global Hypopigmentation Disorders Treatment Market: Pipeline Analysis
Table 03: Global Hypopigmentation Disorders Treatment Market: Pipeline Analysis
Table 04: Global Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 05: Global Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 06: Global Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 07: Global Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 08: North America Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Country, 2016–2026
Table 09: North America Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 10: North America Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 11: North America Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 12: Europe Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 13: Europe Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 14: Europe Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 15: Europe Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 16: Asia Pacific Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17: Asia Pacific Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 18: Asia Pacific Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 19: Asia Pacific Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 20: Latin America Hypopigmentation Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Latin America Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 22: Latin America Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 23: Latin America Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 24: Middle East & Africa Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 25: Middle East & Africa Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 26: Middle East & Africa Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 27: Middle East & Africa Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by End-user, 2016–2026
List of Figures
Figure 01: Global Hypopigmentation Disorders Treatment Market Size (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 02: Global Hypopigmentation Disorders Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 03: Global Hypopigmentation Disorders Treatment Market Value Share, by Treatment, 2017
Figure 04: Global Hypopigmentation Disorders Treatment Market Value Share, by Disease Indication, 2017
Figure 05: Global Hypopigmentation Disorders Treatment Market Value Share, by End-user, 2017
Figure 06: Global Hypopigmentation Disorders Treatment Market Value Share, by Region, 2017
Figure 07: Global Hypopigmentation Disorders Treatment Market Value Share, by Treatment, 2018 and 2026
Figure 08: Global Hypopigmentation Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Topical Drugs, 2016–2026
Figure 09: Global Hypopigmentation Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Laser Therapy, 2016–2026
Figure 10: Global Hypopigmentation Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemical Peels, 2016–2026
Figure 11: Global Hypopigmentation Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Microdermabrasion, 2016–2026
Figure 12: Global Hypopigmentation Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 13: Global Hypopigmentation Disorders Treatment Market Attractiveness Analysis, by Treatment, 2018–2026
Figure 14: Global Hypopigmentation Disorders Treatment Market Value Share, by Disease Indication, 2018 and 2026
Figure 15: Global Hypopigmentation Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Vitiligo, 2016–2026
Figure 16: Global Hypopigmentation Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Albinism, 2016–2026
Figure 17: Global Hypopigmentation Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 18: Global Hypopigmentation Disorders Treatment Market Attractiveness Analysis, by Disease Indication, 2018–2026
Figure 19: Global Hypopigmentation Disorders Treatment Market Value Share, by End-user, 2018 and 2026
Figure 20: Global Hypopigmentation Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2016–2026
Figure 21: Global Hypopigmentation Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Aesthetic Clinics & Dermatology Centers, 2016–2026
Figure 22: Global Hypopigmentation Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 23: Global Hypopigmentation Disorders Treatment Market Attractiveness Analysis, by End-user, 2018–2026
Figure 24: Global Hypopigmentation Disorders Treatment Market Value Share, by Region, 2018 and 2026
Figure 25: Global Hypopigmentation Disorders Treatment Market Attractiveness Analysis, by Region, 2018–2026
Figure 26: North America Hypopigmentation Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 27: North America Hypopigmentation Disorders Treatment Market Value Share, by Country, 2018 and 2026
Figure 28: North America Hypopigmentation Disorders Treatment Market Attractiveness, by Country, 2018–2026
Figure 29: North America Hypopigmentation Disorders Treatment Market Value Share, by Treatment, 2017 and 2026
Figure 30: North America Hypopigmentation Disorders Treatment Market Attractiveness, by Treatment, 2018–2026
Figure 31: North America Hypopigmentation Disorders Treatment Market Value Share, by Disease Indication, 2017 and 2026
Figure 32: North America Hypopigmentation Disorders Treatment Market Attractiveness, by Disease Indication, 2018–2026
Figure 33: North America Hypopigmentation Disorders Treatment Market Value Share, by End-user, 2017 and 2026
Figure 34: North America Hypopigmentation Disorders Treatment Market Attractiveness, by End-user, 2018–2026
Figure 35: Europe Hypopigmentation Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 36: Europe Hypopigmentation Disorders Treatment Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 37: Europe Hypopigmentation Disorders Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 38: Europe Hypopigmentation Disorders Treatment Market Value Share, by Treatment, 2017 and 2026
Figure 39: Europe Hypopigmentation Disorders Treatment Market Attractiveness, by Treatment, 2018–2026
Figure 40: Europe Hypopigmentation Disorders Treatment Market Value Share, by Disease Indication, 2018 and 2026
Figure 41: Europe Hypopigmentation Disorders Treatment Market Attractiveness, by Disease Indication, 2018–2026
Figure 42: Europe Hypopigmentation Disorders Treatment Market Value Share, by End-user, 2017 and 2026
Figure 43: Europe Hypopigmentation Disorders Treatment Market Attractiveness, by End-user, 2018–2026
Figure 44: Asia Pacific Hypopigmentation Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 45: Asia Pacific Hypopigmentation Disorders Treatment Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 46: Asia Pacific Hypopigmentation Disorders Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 47: Asia Pacific Hypopigmentation Disorders Treatment Market Value Share, by Treatment, 2017 and 2026
Figure 48: Asia Pacific Hypopigmentation Disorders Treatment Market Attractiveness, by Treatment, 2018–2026
Figure 49: Asia Pacific Hypopigmentation Disorders Treatment Market Value Share, by Disease Indication, 2017 and 2026
Figure 50: Asia Pacific Hypopigmentation Disorders Treatment Market Attractiveness, by Disease Indication, 2018–2026
Figure 51: Asia Pacific Hypopigmentation Disorders Treatment Market Value Share, by End-user, 2017 and 2026
Figure 52: Asia Pacific Hypopigmentation Disorders Treatment Market Attractiveness, by End-user, 2018–2026
Figure 53: Latin America Hypopigmentation Disorders Treatment Market value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 54: Latin America Hypopigmentation Disorders Treatment Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 55: Latin America Hypopigmentation Disorders Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 56: Latin America Hypopigmentation Disorders Treatment Market Value Share, by Treatment, 2017 and 2026
Figure 57: Latin America Hypopigmentation Disorders Treatment Market Attractiveness, by Treatment, 2018–2026
Figure 58: Latin America Hypopigmentation Disorders Treatment Market Value Share, by Disease Indication, 2018 and 2026
Figure 59: Latin America Hypopigmentation Disorders Treatment Market Attractiveness, by Disease Indication, 2018–2026
Figure 60: Latin America Hypopigmentation Disorders Treatment Market Value Share, by End-user, 2018 and 2026
Figure 61: Latin America Hypopigmentation Disorders Treatment Market Attractiveness, by End-user, 2018–2026
Figure 62: Middle East & Africa Hypopigmentation Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 63: Middle East & Africa Hypopigmentation Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2026
Figure 64: Middle East & Africa Hypopigmentation Disorders Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 65: Middle East & Africa Hypopigmentation Disorders Treatment Market Value Share, by Treatment, 2018 and 2026
Figure 66: Middle East & Africa Hypopigmentation Disorders Treatment Market Attractiveness, by Treatment, 2018–2026
Figure 67: Middle East & Africa Hypopigmentation Disorders Treatment Market Value Share, by Disease Indication, 2018 and 2026
Figure 68: Middle East & Africa Hypopigmentation Disorders Treatment Market Attractiveness, by Disease Indication, 2018–2026
Figure 69: Middle East & Africa Hypopigmentation Disorders Treatment Market Value Share, by End-user, 2018 and 2026
Figure 70: Middle East & Africa Hypopigmentation Disorders Treatment Market Attractiveness, by End-user, 2018–2026
Figure 71: Allergan Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 72: Allergan R&D and Selling, General & Administrative Expenses (US$ Mn), 2016–2017
Figure 73: Allergan Breakdown of Net Sales (% Share), by Business Segment, 2017
Figure 74: Allergan Breakdown of Net Sales (% Share), by U.S. Specialized Therapeutics Segment, 2017
Figure 75: Pierre Fabre Breakdown of Employees (% Share), by Region, 2016
Figure 76: Pierre Fabre Breakdown of Net Sales (% Share), by Business Segment, 2017
Figure 77: Pierre Fabre Breakdown of Net Sales of Pharmaceuticals Division (% Share), by Region, 2016
Figure 78: Pierre Fabre Breakdown of Net Sales of Dermo-Cosmetics Division (% Share), by Region, 2016
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes